Calithera Biosciences Inc. (NASDAQ:CALA) shares rose 4% during trading on Wednesday . The company traded as high as $3.17 and last traded at $3.11, with a volume of 396,117 shares trading hands. The stock had previously closed at $2.99.

CALA has been the topic of a number of analyst reports. Zacks Investment Research raised Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research note on Tuesday, March 22nd. JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $10.48.

The stock’s market cap is $58.38 million. The stock has a 50-day moving average of $4.22 and a 200 day moving average of $5.16.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.05. Equities analysts expect that Calithera Biosciences Inc. will post ($2.15) EPS for the current year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.